Affinity Asset Advisors’s NextCure NXTC Stock Holding History

Affinity Asset Advisors’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$67.1K	Sell	41,960 -199,866	-83%	-$1.48M	﹤0.01%	111
2026 Q1	$2.58M	Sell	241,826 -5,468	-2%	-$66.8K	0.13%	90
2025 Q4	$3.51M	Buy	247,294 +55,412	+29%	+$574K	0.2%	70
2025 Q3	$1.12M	Sell	191,882 -1	-0%	-$5	0.1%	83
2025 Q2	$1.06M	Hold	191,883	–	–	0.14%	69
2025 Q1	$1.11M	Hold	191,883	–	–	0.11%	81
2024 Q4	$1.78M	Hold	191,883	–	–	0.24%	60
2024 Q3	$3.15M	Buy	191,883 +51,220	+36%	+$943K	0.43%	53
2024 Q2	$2.68M	Buy	140,663 +27,410	+24%	+$533K	0.31%	59
2024 Q1	$3.03M	Buy	+113,253	New	+$1.95M	0.38%	65

Other funds holding NXTC

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Affinity Asset Advisors's NXTC Position: Q2 2026 in Review

Affinity Asset Advisors reduced its NextCure (NXTC) stake by 83% in Q2 2026, selling an estimated $1.48M and leaving 41,960 shares worth $67.1K. The position accounts for ﹤0.01% of the portfolio, ranked #111.

Affinity Asset Advisors first reported a position in NXTC in Q1 2024 and has held it in 10 quarters since. The position peaked at $3.51M in Q4 2025. 17 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

Affinity Asset Advisors held 41,960 shares of NextCure worth $67.1K as of Q2 2026.
Affinity Asset Advisors sold 199,866 NextCure shares in Q2 2026, an estimated $1.48M.
NextCure made up ﹤0.01% of Affinity Asset Advisors's portfolio in Q2 2026, its #111 holding.
Affinity Asset Advisors first reported a position in NextCure in Q1 2024 and has held it in 10 quarters since.
Affinity Asset Advisors's NextCure position peaked at $3.51M in Q4 2025.
17 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.